• A special warning that neratinib may cause foetal harm when administered to pregnant women is included in SmPC Section 4.4. Recommendation not to use Nerlynx during pregnancy and further recommendations regarding pregnancy, contraception and breastfeeding are provided in Section 4.6. • Preclinical safety data regarding reproductive toxicity are described in SmPC Section 5.3